<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02733653</url>
  </required_header>
  <id_info>
    <org_study_id>S6051</org_study_id>
    <nct_id>NCT02733653</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Jetstream Atherectomy System (J-SUPREME)</brief_title>
  <official_title>A Prospective, Multicenter, Single-arm Clinical Trial of Jetstream Atherectomy System for the Treatment of Japanese Patients With Symptomatic Occlusive Atherosclerotic Lesions in the Superficial Femoral and/ or Proximal Popliteal Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of the Jetstream
      Atherectomy System for the treatment of Japanese patients with symptomatic occlusive
      atherosclerotic lesions in native superficial femoral artery (SFA) and/or proximal popliteal
      arteries (PPA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, multicenter, single-arm trial evaluating the safety and efficacy of the
      Jetstream Atherectomy System in the treatment of symptomatic occlusive atherosclerotic
      lesions ≤150 mm in length located in the femoropopliteal arteries in subjects with symptoms
      classified as Rutherford categories 2-4.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 25, 2016</start_date>
  <completion_date type="Actual">December 20, 2017</completion_date>
  <primary_completion_date type="Actual">June 29, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Patency Rate</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Procedural Success Rate</measure>
    <time_frame>during procedure</time_frame>
    <description>Bailout stenting or surgical procedure during the index procedure is not needed</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Distal Emboli Requiring Additional Treatment</measure>
    <time_frame>during procedure or within 24 hours post-index procedure</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Reduction in Lesion Stenosis</measure>
    <time_frame>during procedure</time_frame>
    <description>The difference between the percent stenosis prior to treatment with Jetstream and the percent stenosis following treatment with Jetstream.</description>
  </other_outcome>
  <other_outcome>
    <measure>Major Adverse Event (MAE) Rate</measure>
    <time_frame>1 month, 6 months and 12 months</time_frame>
    <description>All-cause death through 1 month, and/or target limb major amputation and/or Target Lesion Revascularization (TLR) through 12 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Primary Patency</measure>
    <time_frame>1 month, 6 months and 12 months</time_frame>
    <description>Percentage (%) of lesions that reach endpoint without a hemodynamically significant stenosis on Duplex Ultrasound (DUS) and without Target Lesion Revascularization (TLR) or, bypass of the target lesion.</description>
  </other_outcome>
  <other_outcome>
    <measure>Assisted Primary Patency</measure>
    <time_frame>1 month, 6 months and 12 months</time_frame>
    <description>Percentage (%) of lesions without TLR and those with TLR (not due to complete occlusion or by-pass) that reach endpoint without restenosis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinically-driven TLR Rate</measure>
    <time_frame>1 month, 6 months and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinically-driven Target Vessel Revascularization (TVR) Rate</measure>
    <time_frame>1 month, 6 months and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Event Rates</measure>
    <time_frame>1 month, 6 months and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Distribution of Rutherford Class</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Distribution of Rutherford Class as compared to baseline at 6 months and 12 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Primary and Secondary Sustained Clinical Improvement</measure>
    <time_frame>1 month, 6 months and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Hemodynamic Improvement</measure>
    <time_frame>1 month, 6 months and 12 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Jetstream Atherectomy System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjunctive therapy with Jetstream Atherectomy System for percutaneous intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Jetstream Atherectomy System</intervention_name>
    <description>A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA</description>
    <arm_group_label>Jetstream Atherectomy System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic, symptomatic lower limb ischemia defined as Rutherford categories 2-4

          -  Stenotic, restenotic or occlusive lesion(s) located in the native SFA and/or PPA of
             which meet all of the following criteria:

               -  Calcified lesions with degree of stenosis ≥70% or occlusions

               -  Guidewire must cross lesion(s) within the true lumen, without a sub-intimal
                  course

               -  Vessel diameter ≥3.0 mm and ≤6.0 mm

               -  Total lesion length (or series of lesions) ≤150mm

               -  Target lesion located at least 3 cm above the inferior edge of the femur by
                  visual estimate

          -  Patent infrapopliteal and popliteal artery

        Exclusion Criteria:

          -  Target lesion/vessel with in-stent restenosis

          -  Target lesion/vessel previously treated with drug-coated balloon &lt;12 months prior to
             the procedure

          -  Target lesion/vessel previously treated with any stent placement, atherectomy, laser
             or other debulking devices prior to the procedure

          -  Subjects who have undergone surgery or endovascular of the SFA/PPA in the target
             vessel to treat atherosclerotic disease within 3 months prior to the index procedure

          -  Use of drug-coated devices, atherectomy, laser or other debulking devices other than
             the Jetstream System, chronic total occlusion (CTO) devices or cutting balloon,
             Angioscore or similar devices in the target limb SFA/PPA during the index procedure

          -  History of major amputation in the target limb

          -  Subject has a history of coagulopathy or hypercoagulable bleeding disorder

          -  Subject with untreatable hemorrhagic disease or platelet count &lt;80,000mm3 or
             &gt;600,000mm3 as baseline assessment.

          -  Concomitant renal failure with a serum creatinine &gt;2.0 mg/dL

          -  Receiving dialysis or immunosuppressant therapy

          -  History of myocardial infarction, or stroke/cerebrovascular accident (CVA) within 6
             months prior to study enrollment

          -  Unstable angina pectoris at the time of the enrollment

          -  Septicemia at the time of enrollment

          -  Presence of other hemodynamically significant outflow lesions in the target limb
             requiring a planned surgical intervention or endovascular procedure within 30 days
             after the index procedure

          -  Presence of aneurysm in the target vessel

          -  Acute ischemia and/or acute thrombosis of the SFA/PPA prior to the index procedure

          -  Perforated vessel as evidenced by extravasation of contrast media prior to the index
             procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kazushi Urasawa, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tokeidai Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nagoya Kyoritsu Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>454-0933</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokura Memorial Hospital</name>
      <address>
        <city>Kokura</city>
        <state>Fukuoka</state>
        <zip>802-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwaki Kyouritsu Hospital</name>
      <address>
        <city>Iwaki</city>
        <state>Fukushima</state>
        <zip>973-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokeidai Memorial Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansai Rosai Hospital</name>
      <address>
        <city>Amagasaki</city>
        <state>Hyogo</state>
        <zip>660-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Yokohama-City Eastern Hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>230-8765</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kishiwada Tokushukai Hospital</name>
      <address>
        <city>Kishiwada</city>
        <state>Osaka</state>
        <zip>596-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kasukabe Chuo General Hospital</name>
      <address>
        <city>Kasukabe</city>
        <state>Saitama</state>
        <zip>344-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyazaki Medical Association Hospital</name>
      <address>
        <city>Miyazaki</city>
        <zip>880-0834</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagano Red Cross Hospital</name>
      <address>
        <city>Nagano</city>
        <zip>380-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>March 24, 2016</study_first_submitted>
  <study_first_submitted_qc>April 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2016</study_first_posted>
  <results_first_submitted>June 27, 2018</results_first_submitted>
  <results_first_submitted_qc>August 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 10, 2018</results_first_posted>
  <last_update_submitted>December 17, 2018</last_update_submitted>
  <last_update_submitted_qc>December 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Superficial Femoral Artery</keyword>
  <keyword>Proximal Popliteal Artery</keyword>
  <keyword>Endovascular therapy</keyword>
  <keyword>Atherectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 29, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT02733653/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 19, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT02733653/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Sixty patients including 10 roll-in patients were enrolled in this trial. Roll-in patients are not included in the endpoint analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Jetstream Atherectomy System - Primary Subject</title>
          <description>Adjunctive therapy with Jetstream Atherectomy System for percutaneous intervention
Jetstream Atherectomy System: A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Jetstream Atherectomy System - Primary Subject</title>
          <description>Adjunctive therapy with Jetstream Atherectomy System for percutaneous intervention
Jetstream Atherectomy System: A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.3" lower_limit="50.0" upper_limit="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Patency Rate</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Jetstream Atherectomy System - Primary Subject</title>
            <description>Adjunctive therapy with Jetstream Atherectomy System for percutaneous intervention
Jetstream Atherectomy System: A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Patency Rate</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Procedural Success Rate</title>
        <description>Bailout stenting or surgical procedure during the index procedure is not needed</description>
        <time_frame>during procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Jetstream Atherectomy System - Primary Subject</title>
            <description>Adjunctive therapy with Jetstream Atherectomy System for percutaneous intervention
Jetstream Atherectomy System: A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success Rate</title>
          <description>Bailout stenting or surgical procedure during the index procedure is not needed</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Rate of Distal Emboli Requiring Additional Treatment</title>
        <time_frame>during procedure or within 24 hours post-index procedure</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Reduction in Lesion Stenosis</title>
        <description>The difference between the percent stenosis prior to treatment with Jetstream and the percent stenosis following treatment with Jetstream.</description>
        <time_frame>during procedure</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Major Adverse Event (MAE) Rate</title>
        <description>All-cause death through 1 month, and/or target limb major amputation and/or Target Lesion Revascularization (TLR) through 12 months</description>
        <time_frame>1 month, 6 months and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Jetstream Atherectomy System - Primary Subject</title>
            <description>Adjunctive therapy with Jetstream Atherectomy System for percutaneous intervention
Jetstream Atherectomy System: A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Event (MAE) Rate</title>
          <description>All-cause death through 1 month, and/or target limb major amputation and/or Target Lesion Revascularization (TLR) through 12 months</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MAE at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAE at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Primary Patency</title>
        <description>Percentage (%) of lesions that reach endpoint without a hemodynamically significant stenosis on Duplex Ultrasound (DUS) and without Target Lesion Revascularization (TLR) or, bypass of the target lesion.</description>
        <time_frame>1 month, 6 months and 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Assisted Primary Patency</title>
        <description>Percentage (%) of lesions without TLR and those with TLR (not due to complete occlusion or by-pass) that reach endpoint without restenosis.</description>
        <time_frame>1 month, 6 months and 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinically-driven TLR Rate</title>
        <time_frame>1 month, 6 months and 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinically-driven Target Vessel Revascularization (TVR) Rate</title>
        <time_frame>1 month, 6 months and 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adverse Event Rates</title>
        <time_frame>1 month, 6 months and 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Distribution of Rutherford Class</title>
        <description>Distribution of Rutherford Class as compared to baseline at 6 months and 12 months</description>
        <time_frame>6 months and 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Rate of Primary and Secondary Sustained Clinical Improvement</title>
        <time_frame>1 month, 6 months and 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Rate of Hemodynamic Improvement</title>
        <time_frame>1 month, 6 months and 12 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Jetstream Atherectomy System - Primary Subject</title>
          <description>Adjunctive therapy with Jetstream Atherectomy System for percutaneous intervention
Jetstream Atherectomy System: A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Arterial intramural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular procedure complication</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The restriction depends on the conditions on the Clinical Study Agreement at each site. The PI must notify the sponsor about the publication and receive the approval from the sponsor prior to any results/data relavant to the J-SUPREME trial to be in public.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yoko Takizawa/Clinical Project Manager</name_or_title>
      <organization>Boston Scientific Japan K.K.</organization>
      <phone>+81-3-6853-7500</phone>
      <email>Yoko.Takizawa@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

